Patient-Centric Development of a Low-Volume, Low-Viscosity, Once Every 4 Weeks (Q4W) Autoinjector Combination Product for Povetacicept
Biologic therapies delivered subcutaneously (SC) are increasingly moving toward at-home self-administration using drug-device combination products. This sh